 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Christine McMahon and Andrew Kent.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.799 |
|
|
|
-
Gil KB, Abbott D, Amaya ML, Schwartz M, Gutman JA, Kent A, Bosma G, Pollyea DA, McMahon CM. Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia. Leuk Lymphoma. 2024 Dec; 65(14):2228-2230.
Score: 0.235
-
Kent A, Gil KB, Jones MK, Linden B, Purev E, Haverkos B, Schwartz M, McMahon C, Amaya M, Smith CA, Bosma G, Abbott D, Rabinovitch R, Milgrom SA, Pollyea DA, Gutman JA. Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective Analysis. Transplant Cell Ther. 2025 Apr; 31(4):267.e1-267.e11.
Score: 0.234
-
Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023 08; 58(8):849-854.
Score: 0.214
-
Santos J, Abbott D, Bosma G, Kent A, Schwartz M, McMahon CM, Gutman J, Pollyea DA, Amaya ML. Comparison of treatment-related and de novo CCUS: a retrospective analysis from two centers. Leuk Lymphoma. 2025 Mar 13; 1-3.
Score: 0.061
-
Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 10 01; 108(10):2616-2625.
Score: 0.055
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|